Does Statin Use Confer a Reduced Risk for COVID-19 Mortality?
BACKGROUND AND PURPOSE:
Bergqvist et al. (PLoS Medicine, 2021) assessed the relationship between statin use and COVID-19 mortality
Routinely collected data
All residents residing in Stockholm (March 1 2019 to February 29 2020)
Statin treatment | Initiated prior to the COVID-19 pandemic to avoid bias due to altered healthcare related to the pandemic
Hazard ratios (HRs) were calculated using multivariable Cox regression models
Subgroup analyses: Age groups | Sexes | Different statin indications | COVID-19 risk groups
Follow-up from March 2020 to November 2020
COVID-19 specific mortality (Swedish Cause of Death Registry)
Statin users: 17.6%
Statin users were
Users: 71.0 years
Non-users: 58.0 years
More likely to be male
More often diagnosed with comorbidities (e.g., ischemic heart disease)
More frequently on anticoagulant and antihypertensive treatments
Less likely to have a university-level education
More likely to have a low disposable income
Less likely to reside in crowded housing
COVID-19 specific mortality
Deaths during follow up: 2545 individuals
Deaths of statin users: 0.5%
Deaths of non-users: 0.2%
Statin treatment was associated with a lowered COVID-19 mortality
Adjusted HR 0.88 (95% CI, 0.79 to 0.97); P=0.01
This association did not vary appreciably across age groups, sexes, or COVID-19 risk groups
There was a moderately lower risk of COVID-19 mortality among statin users
In keeping with previous studies | Current study has the benefit of including not just hospitalized patients, but the total population of Stockholm County
The authors state
In the absence of results from randomized clinical trials, our study can provide some guidance
Specifically, it gives further support for continuing statin treatment for conditions such as cardiovascular disease and hyperlipidemia, in line with current recommendations, during the COVID-19 pandemic
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan